Featured Press Releases

AIM ImmunoTech announces the release of the next CEO Corner segment

AIM ImmunoTech announces the release of the next CEO Corner segment

Renibus Therapeutics to Present RBT-1 at European Association for Cardio-Thoracic Surgery

Renibus Therapeutics to Present RBT-1 at European Association for Cardio-Thoracic Surgery

  • 18 Apr 2024

Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the...

Element Science Receives FDA Approval for the Revolutionary Jewel® Patch Wearable Cardioverter Defibrillator

Element Science Receives FDA Approval for the Revolutionary Jewel® Patch Wearable Cardioverter Defibrillator

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Enhancing Preclinical Research Support, SoBran, Inc. Expands BioScience Services to Los Angeles

Enhancing Preclinical Research Support, SoBran, Inc. Expands BioScience Services to Los Angeles

Precision BioSciences announces a U.S. patent covering PBGENE-HBV for chronic hepatitis B and provides updates on the program

Precision BioSciences announces a U.S. patent covering PBGENE-HBV for chronic hepatitis B and provides updates on the program's status

Niagen Bioscience

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Are Now Available at Over 50 iCRYO Clinics and More Than 900 Clinics Nationwide

  • Niagen Bioscience, Inc
  • 01 Oct 2025
Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

  • Novartis Pharmaceuticals Corporation
  • 01 Oct 2025
CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

  • CollPlant
  • 30 Sep 2025
Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

  • Corstasis Therapeutics Inc.
  • 29 Sep 2025
Leqembi® has received approval for intravenous maintenance treatment in China

Leqembi® has received approval for intravenous maintenance treatment in China

  • BioArctic AB
  • 29 Sep 2025
At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

  • Bayer
  • 25 Sep 2025

Most Popular
October   2025
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.